An open-label, non-randomized, multicenter, two-stage, phase 2 study of TAS-102 and 2nd line therapy for patients with locally advanced or metastatic gastric cancer
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2014
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 02 Mar 2014 According to MD Anderson Cancer Center record; phase is I/II.
- 01 Aug 2006 New trial record.